Harvard Bioscience, Inc. is a developer and manufacturer of research tools and laboratory equipment that support the life sciences industry. The company’s offerings span two primary segments: Research & Discovery, which provides precision instrumentation and consumables for preclinical drug discovery and basic research; and Bioprocess, which delivers bioreactor systems and chromatography solutions for downstream processing in biopharmaceutical manufacturing. Its portfolio includes perfusion bioreactors, microfluidic platforms, medical research systems, and automated liquid handling instruments designed to accelerate scientific discovery and optimize laboratory workflows.
The company’s products serve a diverse customer base comprising academic institutions, government research agencies, biotechnology and pharmaceutical companies, and contract research organizations. Its consumable products—such as electrodes, pumps, and flow meters—are designed for compatibility with its core instrumentation, enabling integrated solutions across cell biology, electrophysiology, pharmacology and bioprocessing applications. Many instruments incorporate digital interfaces and software to facilitate data collection, process control and remote monitoring.
Founded to commercialize the century-old legacy of Harvard Apparatus, the business consolidated under the Harvard Bioscience name in the early 2000s and became publicly listed on the NASDAQ exchange. Headquartered in Holliston, Massachusetts, the company maintains research and manufacturing facilities in North America and Europe, with additional sales offices across Asia, reinforcing its global footprint. It works closely with customers to customize solutions for both routine laboratory needs and complex bioprocess challenges.
Under the leadership of President and Chief Executive Officer James P. Sharp, Harvard Bioscience continues to focus on innovation and strategic partnerships. The management team emphasizes operational efficiency, targeted R&D investments and acquisitions that expand the company’s technological capabilities. By aligning its product roadmap with emerging trends—including single-cell analysis, continuous bioprocessing and advanced automation—Harvard Bioscience aims to support the next generation of life sciences breakthroughs.
AI Generated. May Contain Errors.